{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.4","upperLimit":"11.5","value":"6.9"}]}],"title":"Duration of Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.4","upperLimit":"11.5","value":"9.0"}]}],"title":"Duration of Combined CR and CRh"}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"description":"Duration of CR was defined as the time interval from the first CR to time of relapse. Duration of combined CR and CRh was defined as the time interval from the first CR or CRh to time of relapse. Duration of CR and combined CR and CRh was presented using a Kaplan-Meier estimate.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days), followed by IV infusion of decitabine 20 mg/m\\^2, once daily, on Days 1 to 5 in cycle 2 or the converse. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.","id":"OG000","title":"AML: ASTX727 or IV Decitabine"}],"paramType":"MEDIAN","populationDescription":"Efficacy Analysis Set included all participants who received any amount of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 2.4 years","title":"AML: Duration of Complete Response and Combined CR and CRh Based on IWG 2003 AML Response Criteria","type":"SECONDARY","unitOfMeasure":"months"}